6/29/23, 11:45 PM STEP 8 Pathway Feedback Search Clinical Topics Home Studies STEP 8 STEP 8 Disease Obesity Trial question Is weekly subcutaneous semaglutide superior to daily liraglutide in adults with overweight or obesity without diabetes? Study design Multi-center Open label RCT Population Characteristics of study participants 78.0% female N = 338 22.0% male 338 patients (265 female, 73 male) Inclusion criteria: non-diabetic adults with BMI of 30, or BMI 27 plus at least one weight- related comorbidities Key exclusion criteria: HbA1c 48 mmol/mol; history of type 1 or T2DM mellitus; self-reported change in body weight 5 kg at 90 days of screening Interventions N=126 semaglutide (subcutaneous dose of 2.4 mg once weekly) N=127 liraglutide (subcutaneous dose of 3.0 mg once daily) Primary outcome https://web.pathway.md/studies/recsthZZCH8iYBWt1 1/2 6/29/23, 11:45 PM STEP 8 Pathway Body weight reduction 15.8 % 15.8 11.9 % 7.9 % 6.4 Significant increase 4.0 % NNT = 11 0.0 % Semaglutide Liraglutide Significant increase in body weight reduction (15.8% vs. 6.4%; AD 9.4%, 95% CI 6.8 to 12) Secondary outcomes Significant increase in the percentage of patients achieving a weight reduction of 10% (70.9% vs. 25.6%; OR 6.3, 95% CI 3.5 to 11.2) Significant increase in the percentage of patients achieving a weight reduction of 15% (55.6% vs. 12%; OR 7.9, 95% CI 4.1 to 15.4) Significant increase in the percentage of patients achieving a weight reduction of 20% (38.5% vs. 6%; OR 8.2, 95% CI 3.5 to 19.1) Safety outcomes No significant difference in gastrointestinal adverse events. Conclusion In non-diabetic adults with BMI of 30, or BMI 27 plus at least one weight-related comorbidities, semaglutide was superior to liraglutide with respect to body weight reduction. Reference Domenica M Rubino, Frank L Greenway, Usman Khalid et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):138-150. Open reference URL https://web.pathway.md/studies/recsthZZCH8iYBWt1 2/2